Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

DOI: 10.12659/AOT.914101

Keywords: Epstein-Barr Virus Infections, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Lymphoproliferative Disorders, Transplants

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text